Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Raymond James Financial, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B). The key difference: Raymond James Financial, Inc. is far larger — about 10.5× Dyne Therapeutics Inc. Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Raymond James Financial, Inc. for 75 Days on average.
| DYN | RJF | |
|---|---|---|
Market Cap | $2.86B | $30.15B |
Volume | 3,341,579 | 980,106 |
Sector | Health | Financials |
52-Week High | $26.78 | $181.18 |
52-Week Low | $14.60 | $140.89 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $2.18B | $24.02B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Raymond James Financial (RJF) trades at $157.25, down 0.88% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent earnings beats, revenue growth from $10.9B in 2022 to $13.84B in 2025, and robust profitability margins. Recent news highlights executive leadership changes and a declared $0.54 dividend payable in October 2026.
The stock presents a mixed outlook: attractive valuation multiples and analyst consensus price target of $178.50 suggest upside potential, but bearish technical indicators and rising expenses pose near-term risks. Investment appeal hinges on sustained earnings growth and management's execution amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
